HDI (Hypertension Diagnostics) issued key US patent:
This article was originally published in Clinica
Hypertension Diagnostics (HDI) has gained what it claims is a significant US patent relating to the core technology in its cardiovascular profiling systems. The patent describes methods and apparatus for processing an arterial blood pressure waveform in order to extract clinically useful information regarding the state of the cardiovascular system. HDI's products can provide blood pressure values and non-invasively detect changes in the compliance or elasticity of large and small arteries. Changes in elasticity can indicate whether a patient has underlying vascular disease that might require further evaluation, says the St Paul, Minnesota firm.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.